Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients With Low Time in Therapeutic Range - Study Design
研究概览
详细说明
Investigators will recruit 300 patients with low TTR (<50%) from the Heart Institute- Clinical Hospital- University of São Paulo Medical School (InCor- HCFMUSP). The patients will be randomized into two groups: Traditional Anticoagulation (TA) group and Pharmacogenetic Anticoagulation (PA) group. The study protocol was approved by the Ethics Committee for Medical Research on Human Beings of the Clinical Hospital of the University of São Paulo Medical School (SDC 4033/14/013). Signed informed consent will be obtained from all participants.
Only patients with atrial fibrillation, above 18 years, and with TTR <50% based on the last three values of INR will be included in this study. Patients will not be included if they have reached a stable dose of warfarin, liver dysfunction, alcoholism, use of another anticoagulant, use of chemotherapy, or if they do not meet the inclusion criteria.
研究类型
注册 (预期的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Sao Paulo、巴西、05403900
- Heart Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Only patients with atrial fibrillation, above 18 years, and with TTR <50% based on the last three values of INR will be included in this study.
Exclusion Criteria:
- Patients will not be included if they have reached a stable dose of warfarin, liver dysfunction, alcoholism, use of another anticoagulant, use of chemotherapy, or if they do not meet the inclusion criteria
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Traditional anticoagulation
For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
|
The physician will adjust the dose according to current INR value based on guidelines.
其他名称:
|
实验性的:Pharmacogenetic anticoagulation
For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm.
In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR).
In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
|
The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
time to achieve the therapeutic target
大体时间:12 weeks
|
time to achieve the therapeutic target during 12 weeks of treatment
|
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
TTR (time in the therapeutic range)
大体时间:4 weeks and 12 weeks
|
TTR mean of 4 week and 12 week
|
4 weeks and 12 weeks
|
合作者和调查者
调查人员
- 首席研究员:Alexandre Pereira, M.Sc、Laboratório de Genética e Cardiologia Molecular - Instituto do Coração
出版物和有用的链接
一般刊物
- Santos PC, Marcatto LR, Duarte NE, Gadi Soares RA, Cassaro Strunz CM, Scanavacca M, Krieger JE, Pereira AC. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics. 2015 Jul;16(8):865-76. doi: 10.2217/pgs.15.48. Epub 2015 Jun 8.
- Marcatto LR, Sacilotto L, Bueno CT, Facin M, Strunz CM, Darrieux FC, Scanavacca MI, Krieger JE, Pereira AC, Santos PC. Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. BMC Cardiovasc Disord. 2016 Nov 17;16(1):224. doi: 10.1186/s12872-016-0405-1.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.